Advertisement

Gnosis Offers Pre- and Probiotics Inspired by Nature

Published on: 

Probiotics, often referred to as "friendly bacteria," are live microorganisms that provide numerous health benefits when consumed. These beneficial microorganisms help maintain a healthy balance of microflora in the gut, promoting digestive health and overall well-being.

The probiotics market has witnessed significant growth in recent years, driven by increasing consumer awareness of the health benefits offered by these live microorganisms. Consumers are increasingly seeking natural ways to maintain their health and well-being, leading to a surge in the popularity of probiotic products.

The market offers a variety of probiotic strains, each with its unique health benefits.

It is important to note that not all probiotics are created equal. Different strains offer different benefits.

At Gnosis by Lesaffre, we believe in science and we partner with nature to design the best probiotics and prebiotics for dietary supplements. Our biotic range has been developed to support gut health, immune health but also wellness and women health.

Lynside® Pro SCB, The premier S.boulardii helps to prevent dysbiosis & restore microbiota

Gnosis by Lesaffre has produced for decades the Premier S.boulardii, Lynside® PRO SCB.

Lynside® PRO SCB is a Saccharomyces cerevisiae var. boulardii, a proprietary strain of Lesaffre registered as CNCM I-3799.

S.boulardii is the most documented probiotic yeast with more than 50 years of clinical research that supports the gut barrier defense system.S. boulardii is clinically proven to reduce diarrhea in adults and children and to help restore a balanced microbiota.

Thanks to more than 170 years of experience of Lesaffre in yeast and a unique drying process, Gnosis by Lesaffre ensures an optimal stability and a long shelf life to Lynside® PRO SCB. S. boulardii is very resistance to the gastric environment that offers the possibility to reach the colon alive at a high rate and can be used with antibiotic treatment.

ibSium®: A Reference Probiotic Yeast to Improve Intestinal Comfort and Quality of Life

We all have unique microbiota that reflects our digestive and overall well-being. But every day, many factors can impact this natural balance (i.e., diet, stress, medication, lifestyle, etc.) and induce an "instability of intestinal diversity," which is often the starting point for digestive discomfort and symptoms.

For hundreds of millions of people worldwide, gastrointestinal symptoms significantly impact their daily quality of life. Irritable bowel syndrome (IBS) symptoms lead to considerable impairment of health-related quality of life and high healthcare costs.

ibSium® is a natural probiotic yeast developed by Gnosis by Lesaffre. This reference strain is patented and registered under the name S. cerevisiae CNCM I-3856.

ibSium® has demonstrated clinically proven efficacy on intestinal comfort, thanks to 4 double-blind, placebo-controlled clinical studies and a meta-analysis.

Indeed, these studies confirmed that daily administration of this patented and exclusive probiotic yeast (S.cerevisiae CNCM I-3856) can relieve occasional abdominal pain and improve the quality of life of people suffering from IBS.

  • 63% of volunteers experienced a significant reduction in abdominal pain (1)
  • 14.6% of reduction in bloating (2)
  • Normalization of stool consistency was observed within 4 weeks (3)

Today, with 4 clinical studies (on over 1100 subjects) supporting its efficacy, a daily supplementation with ibSium® ,our probiotic strain Saccharomyces cerevisiae CNCM I-3856 offers a complete digestive comfort.

LifeinU® L.Rhamnosus GG: the reliable probiotic bacteria to be free from digestive discomfort

Lacticaseibacillus and Bifidobacterium are among the most common strains used in probiotic formulations. These strains are known for their ability to support digestive health and boost the immune system.

Lacticaseibacillus rhamnosus GG is one of the most studied probiotic bacterium used in various products worldwide to support digestive health by restoring and maintaining a balanced gastrointestinal flora, protecting the gut from antibiotic-associated diarrhea, and protecting against acute diarrhea.

It has been demonstrated that L. rhamnosus GG helps to reduce

> the occurrence and duration of diarrhea caused by antibiotics or gastrointestinal symptoms

> symptoms (gas, bloating, abdominal pain) in children IBS (Irritable Bowel Syndrome)

> abdominal pain for children (4-5)

LifeinU® L.rhamnosus GG is a high-quality strain of L. rhamnosus GG that provides quality, stability, substainability, and reliability thanks to the experience of Lesaffre Groupe for 170 years.

LifeinU® BSCU1: a unique sporulated probiotic that may empower the consumer’s Immune response

Probiotics also play a crucial role in boosting the immune system. They stimulate the production of antibodies, enhancing the body's ability to fight off harmful bacteria and viruses.

The immunity market is adaptive to the changes of our constantly evolving world, and probiotics are an excellent example of an alternative to the staple immunity ingredients.

According to the 2020 Council for Responsible Nutrition report “Supplemental Security Income” (SSI), 82% of Americans know that probiotics may support their immune health. This report explains why probiotics now rank in the top 10 ingredients dedicated to immunity (6). The stress and fatigue of modern life can weaken our natural defenses. Consumers are now aware that optimizing their immune system is key to staying healthy and performing well every day.LifeinU® BSCU1 is the key to optimizing the immune system.

LifeinU® BSCU1 is a unique and patented strain of Bacillus subtilis (registered under the number CNCM I-2745) dedicated to supporting the immune system. It is one of the most stable probiotics on the market, making it suitable for dietary supplements and functional foods.

The clinical study(7) of Gnosis by Lesaffre’s showed that supplementation with LifeinU BSCU1 provides a double-protective effect. First, it significantly increases the sIgA level in the respiratory tract by 45% and in the intestine by 87%. Secondly, it is associated with a 31% reduction of the relative risk to report an infectious episode. Further, the reduction in the frequency of common colds is a key effect sought by consumers, and consumption of this probiotic has been shown to reduce the number of days with an infectious episode by an average of 2.8.

Quatreflora™: A natural breakthrough for vaginal health:

Women’s microbiota is very sensitive and can be disrupted by a number of factors and life events such as hormonal variations, antibiotics use, stress, lifestyle, etc. These circumstances can affect the delicate balance of the vaginal microbiota and favour the growth of pathogenic microorganisms, thus negatively impacting women’s quality of life on a daily basis.

Candidiasis is one of the most prevalent causes of vaginal discomfort in women of reproductive age and is characterized by the disruption of the vaginal microbiota composition. About 90% of vaginal candidiasis infections are caused by Candida albicans overgrowth. Vaginal candidiasis is a widespread issue, with over 75% of women worldwide experiencing at least one episode (8) in their lifetime, 40% to 50% of them dealing with a second episode and 4 to 8% of all women suffering from recurrences (4 or more per year) (9)

Quatreflora is new probiotic approach for women’s intimate health concerns. Produced from a patented strain of Saccharomyces cerevisiae CNCM I-3856, Quatreflora™ is a probiotic yeast that balances and optimizes vaginal flora and protects against bacterial and yeast vaginosis.

This probiotic yeast is able to adhere to the vaginal epithelium forming a protective barrier against pathogens. A clinical study showed that the oral supplementation with Quatreflora™ during 2 months decreased vaginal load of C.albicans by 57 % vs 33 % in the placebo group and the risk of recurrence by 54%. (10)

The oral supplementation efficiency has also been clinically demonstrated by showing the ability of this probiotic yeast to migrate from intestine to vagina. The advantage of this oral supplementation is also to allow a dual action of the probiotic both in the intestine and in the vagina. This is of particular interest as the intestine is known to be a reservoir of pathogens and a source of vaginal infections. (11)

References:

  1. Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, Justen P, Desreumaux P. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Digestive and Liver Disease; 2015 February; 47(2):119- 124.
  2. Spiller RS, Pelerin F, Cayzeele Decherf A, Maudet C, Housez B, Cazaubiel M, Justen P. Randomized, double-blind, placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in Irritable Bowel Syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterology Journal; 2016, vol.4, 353-362.
  3. Gayathri R, Aruna T, Malar S, Shilpa B, Dhanasekar KR. Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome. International Journal of Colorectal Disease ; 2020, 35, 139-145.
  4. SZAJEWSKA, Hania, KOŁODZIEJ, Maciej, GIERUSZCZAK‐BIAŁEK, Dorota, et al. Systematic review with meta‐analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children–a 2019 update. Alimentary pharmacology & therapeutics, 2019, vol. 49, no 11, p. 1376-1384.
  5. HORVATH, A., DZIECHCIARZ, P., et SZAJEWSKA, H. Meta‐analysis: Lactobacillus rhamnosus GG for abdominal pain‐related functional gastrointestinal disorders in childhood. Alimentary pharmacology & therapeutics, 2011, vol. 33, no 12, p. 1302-1310.​
  6. CRN’s 2020 Survey
  7. Lefevre M, et al. Probiotic strain LifeinU™ BSCU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. Immun Ageing. 2015 Dec 3;12:24. Doi: 10.1186/s12979-015-0051-y.
  8. Center for Disease Control and Prevention (CDC). Sexually transmitted disease treatment guidelines. 2015
  9. D.W. Denning, M. Kneale, R. Rautemaa-Richardson, J.D. Sobel. Global prevalence of recurrent vulvovaginal candidiasis. ePoster, Session STD and other genital infections, ECCMID 2014 Barcelona, Spain
  10. Saccharomyces cerevisiae CNCM I-3856 as a Natural Breakthrough for Vaginal Health: A Clinical Study. Cayzeele Decherf A, Pélerin F and Jüsten P, 2017, Medical Journal of Obstetrics and Gynecology 5(4): 1112
  11. Recovery of saccharomyces cerevisiae CNCM i-3856 in vaginal samples of healthy women after oral administration- Decherf ADehay EBoyer M et al.Nutrients (2020) 12(8) 1-16
Advertisement
Advertisement